FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361866993> ?p ?o ?g. }

• W4361866993 endingPage "9142" @default.
• W4361866993 startingPage "9134" @default.
• W4361866993 abstract "Abstract Vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis by stimulating the proangiogenic signaling of endothelial cells via activation of VEGF receptor (VEGFR) tyrosine kinases. Therefore, VEGFRs are an attractive therapeutic target for cancer treatment. In the present study, we show that a quinoline-urea derivative, KRN951, is a novel tyrosine kinase inhibitor for VEGFRs with antitumor angiogenesis and antigrowth activities. KRN951 potently inhibited VEGF-induced VEGFR-2 phosphorylation in endothelial cells at in vitro subnanomolar IC50 values (IC50 = 0.16 nmol/L). It also inhibited ligand-induced phosphorylation of platelet-derived growth factor receptor-β (PDGFR-β) and c-Kit (IC50 = 1.72 and 1.63 nmol/L, respectively). KRN951 blocked VEGF-dependent, but not VEGF-independent, activation of mitogen-activated protein kinases and proliferation of endothelial cells. In addition, it inhibited VEGF-mediated migration of human umbilical vein endothelial cells. Following p.o. administration to athymic rats, KRN951 decreased the microvessel density within tumor xenografts and attenuated VEGFR-2 phosphorylation levels in tumor endothelium. It also displayed antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer. Furthermore, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) analysis revealed that a significant reduction in tumor vascular hyperpermeability was closely associated with the antitumor activity of KRN951. These findings suggest that KRN951 is a highly potent, p.o. active antiangiogenesis and antitumor agent and that DCE-MRI would be useful in detecting early responses to KRN951 in a clinical setting. KRN951 is currently in phase I clinical development for the treatment of patients with advanced cancer. (Cancer Res 2006; 66(18): 9134-42)" @default.
• W4361866993 created "2023-04-05" @default.
• W4361866993 creator A5018723527 @default.
• W4361866993 creator A5027185140 @default.
• W4361866993 creator A5038509746 @default.
• W4361866993 creator A5040977084 @default.
• W4361866993 creator A5042694447 @default.
• W4361866993 creator A5050476600 @default.
• W4361866993 creator A5055114425 @default.
• W4361866993 creator A5058213173 @default.
• W4361866993 creator A5060268565 @default.
• W4361866993 creator A5062150969 @default.
• W4361866993 creator A5064131992 @default.
• W4361866993 creator A5066617722 @default.
• W4361866993 creator A5074900244 @default.
• W4361866993 creator A5078951651 @default.
• W4361866993 date "2006-09-15" @default.
• W4361866993 modified "2023-10-17" @default.
• W4361866993 title "KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties" @default.
• W4361866993 cites W1493048246 @default.
• W4361866993 cites W1539571840 @default.
• W4361866993 cites W1948205405 @default.
• W4361866993 cites W1988307856 @default.
• W4361866993 cites W1991175004 @default.
• W4361866993 cites W1996451325 @default.
• W4361866993 cites W2000292756 @default.
• W4361866993 cites W2001658518 @default.
• W4361866993 cites W2006202974 @default.
• W4361866993 cites W2014148719 @default.
• W4361866993 cites W2032882287 @default.
• W4361866993 cites W2049582178 @default.
• W4361866993 cites W2050037358 @default.
• W4361866993 cites W2063036052 @default.
• W4361866993 cites W2071895235 @default.
• W4361866993 cites W2073262381 @default.
• W4361866993 cites W2075200239 @default.
• W4361866993 cites W2076424556 @default.
• W4361866993 cites W2090944837 @default.
• W4361866993 cites W2091872802 @default.
• W4361866993 cites W2096704713 @default.
• W4361866993 cites W2097373408 @default.
• W4361866993 cites W2108610949 @default.
• W4361866993 cites W2120226003 @default.
• W4361866993 cites W2121500370 @default.
• W4361866993 cites W2123703868 @default.
• W4361866993 cites W2125233609 @default.
• W4361866993 cites W2127670903 @default.
• W4361866993 cites W2140765540 @default.
• W4361866993 cites W2157769714 @default.
• W4361866993 cites W2165760078 @default.
• W4361866993 cites W2253046940 @default.
• W4361866993 cites W4233232262 @default.
• W4361866993 doi "https://doi.org/10.1158/0008-5472.can-05-4290" @default.
• W4361866993 hasPublicationYear "2006" @default.
• W4361866993 type Work @default.
• W4361866993 citedByCount "141" @default.
• W4361866993 countsByYear W43618669932012 @default.
• W4361866993 countsByYear W43618669932013 @default.
• W4361866993 countsByYear W43618669932014 @default.
• W4361866993 countsByYear W43618669932015 @default.
• W4361866993 countsByYear W43618669932016 @default.
• W4361866993 countsByYear W43618669932017 @default.
• W4361866993 countsByYear W43618669932018 @default.
• W4361866993 countsByYear W43618669932019 @default.
• W4361866993 countsByYear W43618669932020 @default.
• W4361866993 countsByYear W43618669932021 @default.
• W4361866993 countsByYear W43618669932022 @default.
• W4361866993 countsByYear W43618669932023 @default.
• W4361866993 crossrefType "journal-article" @default.
• W4361866993 hasAuthorship W4361866993A5018723527 @default.
• W4361866993 hasAuthorship W4361866993A5027185140 @default.
• W4361866993 hasAuthorship W4361866993A5038509746 @default.
• W4361866993 hasAuthorship W4361866993A5040977084 @default.
• W4361866993 hasAuthorship W4361866993A5042694447 @default.
• W4361866993 hasAuthorship W4361866993A5050476600 @default.
• W4361866993 hasAuthorship W4361866993A5055114425 @default.
• W4361866993 hasAuthorship W4361866993A5058213173 @default.
• W4361866993 hasAuthorship W4361866993A5060268565 @default.
• W4361866993 hasAuthorship W4361866993A5062150969 @default.
• W4361866993 hasAuthorship W4361866993A5064131992 @default.
• W4361866993 hasAuthorship W4361866993A5066617722 @default.
• W4361866993 hasAuthorship W4361866993A5074900244 @default.
• W4361866993 hasAuthorship W4361866993A5078951651 @default.
• W4361866993 hasBestOaLocation W43618669931 @default.
• W4361866993 hasConcept C101544691 @default.
• W4361866993 hasConcept C11960822 @default.
• W4361866993 hasConcept C126322002 @default.
• W4361866993 hasConcept C134018914 @default.
• W4361866993 hasConcept C146285616 @default.
• W4361866993 hasConcept C14858245 @default.
• W4361866993 hasConcept C167734588 @default.
• W4361866993 hasConcept C170493617 @default.
• W4361866993 hasConcept C185592680 @default.
• W4361866993 hasConcept C2777025900 @default.
• W4361866993 hasConcept C2777553839 @default.
• W4361866993 hasConcept C2780394083 @default.
• W4361866993 hasConcept C42362537 @default.
• W4361866993 hasConcept C502942594 @default.

• next